News In Brief


BMJ 2007; 335 doi: (Published 22 November 2007) Cite this as: BMJ 2007;335:1064

Use of osteoarthritis drug is suspended in UK: The UK Medicines and Healthcare Products Regulatory Agency has suspended sales of the osteoarthritis drug lumiracoxib (Prexige), pending a Europe-wide review next month. The latest global safety data have shown an increase in the risk of serious liver problems with the licensed dose of 100 mg—in some cases after treatment of less than a month. Around 5000 UK patients have received the drug since it became available in 2005, and 8.5 million prescriptions have been …

View Full Text

Sign in

Log in through your institution